La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Avalon GloboCare Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Avalon GloboCare ha un patrimonio netto totale di $6.1M e un debito totale di $8.3M, che porta il suo rapporto debito/patrimonio netto a 137.2%. Le sue attività totali e le sue passività totali sono rispettivamente $20.3M e $14.3M.

Informazioni chiave

185.5%

Rapporto debito/patrimonio netto

US$8.19m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$200.57k
Patrimonio netto	US$4.42m
Totale passività	US$15.10m
Totale attività	US$19.52m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { ALBT di $777.8K ) non coprono le sue passività a breve termine ( $7.8M ).

Passività a lungo termine: Le attività a breve termine di ALBT ( $777.8K ) non coprono le sue passività a lungo termine ( $6.5M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 132.2% ) di ALBT è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di ALBT è aumentato da 22.1% a 137.2% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ALBT ha una cash runway sufficiente per 1 mesi in base all'ultimo flusso di cassa libero riportato, ma da allora ha raccolto capitale aggiuntivo.

Previsione Cash Runway: Si prevede che ALBT disponga di liquidità sufficiente per 1 mesi in base alle stime del flusso di cassa libero, ma da allora ha raccolto capitale aggiuntivo.

Avalon GloboCare Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. announced delayed annual 10-K filing

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

Recent updates

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54

First half earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane